PubHawk
September 2025 PMID 40888717

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Milind Y Desai, Anjali T Owens, Theodore Abraham, Iacopo Olivotto, Pablo Garcia-Pavia, Renato D Lopes, Perry Elliott, Fabio Fernandes, Nicolas Verheyen, Lars Maier, Benjamin Meder, Olga Azevedo, Hiroaki Kitaoka, Kathy Wolski, Qiuqing Wang

Full text PDF Download social card

Mentions

113
Peak: 61 in Aug 2025
across 5 sources since Feb 2025

Extended reach

3,311,982
potential audience

Total likes

480

Video views

257

Mentions per month

Feb 2025 – Oct 2025

Where it's discussed

  • X / Twitter102 posts
  • News5 articles
  • Bluesky2 posts
  • YouTube2 videos
  • Instagram2 posts

AI synopsis

What people are saying

The discussions center around the trial results, citing phrases like 'did not significantly improve' and 'more patients had reduced LVEF,' demonstrating careful analysis of the study's outcomes. Words like 'significantly' and 'limitations' reflect a critical tone, while references to trial design and specific metrics show a keen interest and engagement with the research's details.

AgreementModerate agreement

Most discussions acknowledge the trial results, emphasizing that mavacamten did not show significant improvements, indicating moderate consensus on its limited effectiveness.

InterestModerate interest

The discussions reflect moderate curiosity, with many references to the trial and its methods, but limited personal opinions or speculative comments.

EngagementModerate engagement

Participants reference specific trial details, such as peak oxygen uptake and LVEF reductions, suggesting a solid level of engagement with the research findings.

ImpactModerate impact

The dialogues highlight concerns about the drug’s efficacy and side effects, implying the publication could influence future clinical approaches, which signifies a moderate level of impact.

Abstract in brief

  • Mavacamten is approved for treating obstructive hypertrophic cardiomyopathy (HCM), but its effects on nonobstructive HCM were tested in a phase 3 clinical trial to evaluate functional capacity and health status.
  • The trial involved 580 patients, randomly divided between receiving mavacamten and a placebo over 48 weeks, measuring changes in peak oxygen uptake and Kansas City Cardiomyopathy Questionnaire scores.
  • Results showed slight improvements in fitness and health status for the mavacamten group, but these were not statistically significant compared to placebo, raising concerns about side effects like reduced ejection fraction.
Read the full abstract

Top posts

Most liked on X and Bluesky
Abdulla A. Damluji, MD, PhD
@DrDamluji · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 289 likes · 55 shares · 16,025 followers View post →
NEJM
@NEJM · X

Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Editorial: Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions https://t.co/erq8eTjM5s https://t.co/oFZb90WZ3y

Sep 14, 2025 · 24 likes · 7 shares · 933,223 followers View post →
NEJM
@NEJM · X

Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Editorial: Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions https://t.co/erq8eTjM5s https://t.co/jxDNAjle4J

Aug 31, 2025 · 22 likes · 6 shares · 933,223 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 symptomatic nHCM patients worldwide. It assesses improvements at Week 48 in https://t.co/Z6pJ1WjaON

Aug 21, 2025 · 18 likes · 2 shares · 3,249 followers View post →
NEJM
@NEJM · X

New in the September 11, 2025, issue of NEJM: Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) https://t.co/LUjGMkf5UP Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Multidomain https://t.co/cUa0z4ANjn

Sep 11, 2025 · 17 likes · 3 shares · 933,223 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo @hfcollaboratory @iheartfunction @NEJM https://t.co/13d2M5Ws6d

Sep 14, 2025 · 16 likes · 3 shares · 3,249 followers View post →

All mentions

Mark
@headass_deadass · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 27, 2025 · 7 shares · 777 followers View post →
STITCHES Medicine - the Best of Medical Research
@STITCHESMed · X

Mavacamten fails to substantially improve functional capacity or symptoms in patients with symptomatic nonobstructive hypertrophic cardiomyopathy. by Desai MY, Owens AT (...) Nissen SE et 22 al. in N Engl J Med https://t.co/ltA435vAo2 #MedX #MedResearch

Sep 20, 2025 · 97 followers View post →
NEJM.org
@nejm.org · Bluesky

In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. Full ODYSSEY-HCM phase 3 trial results and Research Summary: nej.md/4oSZx2m #MedSky

Sep 16, 2025 · 3 likes · 2 shares View post →
Daniel Foster
@innofoster · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 15, 2025 · 7 shares · 14 followers View post →
Dr Duncan Hogg
@drduncanhogg · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Sep 15, 2025 · 3 shares · 1,301 followers View post →
Hany Ragy
@Hragy · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 15, 2025 · 7 shares · 80,683 followers View post →
George Kolostoumpis
@gkolost · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 15, 2025 · 7 shares · 2,081 followers View post →
Fran G.U.
@Francistomati · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 15, 2025 · 7 shares · 266 followers View post →
Zuilma Vásquez
@VazyurVasquez · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Sep 14, 2025 · 7 shares · 4,446 followers View post →
juan lopez
@jd1lopez · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Sep 14, 2025 · 3 shares · 1,074 followers View post →
旅人 tabito
@tabibito250 · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/PWmWluMsjp

Sep 14, 2025 · 1,078 followers View post →
Takuya Kishi @ねこ好き循環器内科医
@tkishi_cardiol · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Sep 14, 2025 · 3 shares · 14,962 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo @hfcollaboratory @iheartfunction @NEJM https://t.co/13d2M5Ws6d

Sep 14, 2025 · 16 likes · 3 shares · 3,249 followers View post →
NEJM
@NEJM · X

Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Editorial: Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions https://t.co/erq8eTjM5s https://t.co/oFZb90WZ3y

Sep 14, 2025 · 24 likes · 7 shares · 933,223 followers View post →
Dr.
@Bb_281 · X

RT @NEJM: New in the September 11, 2025, issue of NEJM: Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial…

Sep 11, 2025 · 3 shares · 5 followers View post →
Marko
@Markotelomerase · X

RT @NEJM: New in the September 11, 2025, issue of NEJM: Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial…

Sep 11, 2025 · 3 shares · 71 followers View post →
NEJM
@NEJM · X

New in the September 11, 2025, issue of NEJM: Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) https://t.co/LUjGMkf5UP Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Multidomain https://t.co/cUa0z4ANjn

Sep 11, 2025 · 17 likes · 3 shares · 933,223 followers View post →
Philipp Lopatka
@LopatkaPhilipp · X

RT @DrDamluji: Check out my latest article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results from the ODYSSEY-…

Sep 7, 2025 · 1 share · 201 followers View post →
Philipp Lopatka
@LopatkaPhilipp · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 7, 2025 · 55 shares · 201 followers View post →
ドクターT＠循環器内科
@heart_doctor_t · X

ODYSSEY-HCM試験 症候性の非閉塞性肥大型心筋症におけるマバカムテン peakVO2やKCCQを有意に改善せず Desai MY, Owens AT, Abraham T, et al. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. PMID: 40888717 #ESCCongress2025 https://t.co/liKpitKTfF

Sep 5, 2025 · 1 like · 12 followers View post →
Z. Dindane
@ZouDindaneMD · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 2, 2025 · 55 shares · 487 followers View post →
Jamael Hoosain
@TheRealJamael · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 2, 2025 · 55 shares · 529 followers View post →
Jeny Torres Gonzales
@JenyTorresg · X

RT @Ed_Alania: https://t.co/MuvqL8oIRd

Sep 1, 2025 · 1 share · 72 followers View post →
John Rickards
@JohnRickards8 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 135 followers View post →
Victor De La Espriella Badel
@vimadelaeb · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 446 followers View post →
Motte
@AlvaradomotteA · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 496 followers View post →
Daniel Pita, MD
@danpita · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 1,337 followers View post →
Deya Alkhatib, MD, FACC, FSCMR,FSCCT, FASE,FSCAI
@Deya_AlkhatibMD · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 1,876 followers View post →
nardicp@gmail.com
@nardicpgmailco1 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 38 followers View post →
Mario092
@Mario0921170302 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 3 followers View post →
Lica
@lica_osnts · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 17 followers View post →
TAVB
@AfifahRizkah · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 7 followers View post →
Sección Cardiopatías Familiares y Genética CV SEC
@seccCFyGenetCV · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 1,881 followers View post →
Tornike Kvariantashvili, MD
@TornikeK_MD · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 106 followers View post →
Alejandro Riva Palacio
@alexrp22 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 26 followers View post →
AngryPhDstudent❗️❗️❗️
@ONNESHA092 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 199 followers View post →
Vladyslav Kavalerchyk
@echo_stepbystep · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Sep 1, 2025 · 55 shares · 18,300 followers View post →
Seigo Izumo
@SeigoIzumo · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 4,041 followers View post →
Carlos Cabrera Arroyo
@cabrera_arroyo · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 1,875 followers View post →
a_nt0nella
@a_nt0nella · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 732 followers View post →
Zuilma Vásquez
@VazyurVasquez · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 4,446 followers View post →
Florencia Cantora
@Florcantora_ · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 25 followers View post →
Syed Ali Naqvi
@SyedYNaqvi1 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 2,594 followers View post →
Aaysha Cader
@aayshacader · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 9,112 followers View post →
SultanSBAlSA
@SultanSBAlSA · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 48 followers View post →
Steven C. Stroud
@ChaseStroudMD · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 320 followers View post →
Edgardo Alania
@Ed_Alania · X

https://t.co/MuvqL8oIRd

Aug 31, 2025 · 1 like · 1 share · 10,405 followers View post →
Amr Moustafa
@amr_o_moustafa · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 617 followers View post →
د . احمد سمان
@Ahmed43101178 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 6,403 followers View post →
EOLO MORANDI JR.
@eolojr · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Aug 31, 2025 · 2 shares · 548 followers View post →
Abstream
@abstreamme · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy #science #publication #research #publications https://t.co/6eMAK26fQw

Aug 31, 2025 · 789 followers View post →
青木 秀輔
@Shusuke_AOKI · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 119 followers View post →
excalibur
@drexcalibur61 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 117 followers View post →
CremerCardio
@CremerCardio · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Aug 31, 2025 · 2 shares · 155 followers View post →
Antonio Vega
@cardiotoni · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 34 followers View post →
Anjali Owens
@tikuowens · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 400 followers View post →
Andromeda
@outrageeouss · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 729 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo. @NEJM @DrMarthaGulati @SJGreene_md @gcfmd https://t.co/CR8d16T0Sd

Aug 31, 2025 · 7 likes · 2 shares · 3,249 followers View post →
Aaron Scott
@FuturePH_Scott · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 27 followers View post →
Tatyana Shamliyan
@ShamliyanTA · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 267 followers View post →
Silvia Serrano A.
@SilviaSerranoA3 · X

RT @NEJM: Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/z…

Aug 31, 2025 · 6 shares · 65 followers View post →
Ash Paul
@pash22 · X

@Hragy @JACCJournals @DesaiMilindY @djc795 Yup, the @NEJM article by @DesaiMilindY et al says "Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo" https://t.co/a1LWbkY8mU

Aug 31, 2025 · 32,319 followers View post →
David de las Cuevas
@DaviddlCuevas · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 1,393 followers View post →
NEJM
@NEJM · X

Original Article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) https://t.co/zHc6oYJUgK Editorial: Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions https://t.co/erq8eTjM5s https://t.co/jxDNAjle4J

Aug 31, 2025 · 22 likes · 6 shares · 933,223 followers View post →
Echocardiography
@echocardiac · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 31,886 followers View post →
Sahil
@Imsahil258 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 173 followers View post →
Sachin Mehta
@SachMehta · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 377 followers View post →
ALKINDY Abdulrhman
@Abdul_alkindy · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 31, 2025 · 55 shares · 891 followers View post →
Alejandro I. Pérez Cabeza
@alejandroipc2 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 1,167 followers View post →
Murayama
@murayama_1224 · X

RT @HiroyukiOkura: ODYSSEY-HCM Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https…

Aug 30, 2025 · 1 share · 404 followers View post →
Natsir Ramadhan
@natsiradhan · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 557 followers View post →
HUGO COLOMBO MD
@HCOLOMBO1958 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 1,123 followers View post →
Sophia
@ravisha22326557 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 157 followers View post →
Kingston
@kianboy · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 459 followers View post →
Hany Ragy
@Hragy · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 80,683 followers View post →
Cagri ‘Chara’ Aksu, MD
@CagriAksuMD · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 188 followers View post →
Dr. Luiz Silva
@DrLuizSilva1 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 396 followers View post →
Ritu Thamman MD
@iamritu · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 31,906 followers View post →
Khalid Minhas, MD FACC
@minhaskh · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 11,357 followers View post →
Michael Vu, DO
@michaelhvu · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 1,033 followers View post →
Hiroyuki Okura, MD(大倉宏之)
@HiroyukiOkura · X

ODYSSEY-HCM Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/wcmuGwIbWC

Aug 30, 2025 · 7 likes · 1 share · 1,140 followers View post →
Carlos Ávila
@CarlosAR016 · X

RT @DrDamluji: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 55 shares · 271 followers View post →
Abdulla A. Damluji, MD, PhD
@DrDamluji · X

Check out my latest article: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results from the ODYSSEY-HCM Trial https://t.co/EnS0xgl9PL via @LinkedIn

Aug 30, 2025 · 2 likes · 1 share · 16,025 followers View post →
Abdulla A. Damluji, MD, PhD
@DrDamluji · X

Aug 30, 2025 · 2 likes · 16,025 followers View post →
Abdulla A. Damluji, MD, PhD
@DrDamluji · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM

Aug 30, 2025 · 289 likes · 55 shares · 16,025 followers View post →
NEJM.org
@nejm.org · Bluesky

Aug 30, 2025 · 9 likes · 3 shares View post →
Juan Senior
@jsenior64 · X

https://t.co/r8CmHKNUNf

Aug 30, 2025 · 11,089 followers View post →
Eugenio Cingolani, MD
@EugenioCingolan · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/eAYyn17WAG

Aug 30, 2025 · 3,401 followers View post →
Kingston
@kianboy · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Aug 30, 2025 · 2 shares · 459 followers View post →
Takuya Kishi @ねこ好き循環器内科医
@tkishi_cardiol · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten…

Aug 30, 2025 · 2 shares · 14,962 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo. https://t.co/dEjV4G2PiB https://t.co/5KcR6Bdigh

Aug 30, 2025 · 11 likes · 2 shares · 3,249 followers View post →
Dr Duncan Hogg
@drduncanhogg · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of…

Aug 21, 2025 · 2 shares · 1,301 followers View post →
د . احمد سمان
@Ahmed43101178 · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of…

Aug 21, 2025 · 2 shares · 6,403 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 symptomatic nHCM patients worldwide. It assesses improvements at Week 48 in https://t.co/Z6pJ1WjaON

Aug 21, 2025 · 18 likes · 2 shares · 3,249 followers View post →
SultanSBAlSA
@SultanSBAlSA · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of…

Aug 17, 2025 · 3 shares · 48 followers View post →
د . احمد سمان
@Ahmed43101178 · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of…

Aug 17, 2025 · 3 shares · 6,403 followers View post →
Ahmad Masri
@MasriAhmadMD · X

RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of…

Aug 17, 2025 · 3 shares · 9,065 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 symptomatic nHCM patients worldwide. It assesses improvements at Week 48 in https://t.co/xR7xGlG8L5

Aug 17, 2025 · 16 likes · 3 shares · 3,249 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

Five Studies We Are Looking For Ward in Heart Failure to at ESC 2025 Madrid Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 https://t.co/hHNcvZClJI

Jul 13, 2025 · 8 likes · 3,249 followers View post →
AngryPhDstudent❗️❗️❗️
@ONNESHA092 · X

RT @drbennisahmed: ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:4 Mavacamten in Symptomatic Nonobstructive Hypertroph…

Jul 8, 2025 · 3 shares · 199 followers View post →
Natsir Ramadhan
@natsiradhan · X

RT @drbennisahmed: ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:4 Mavacamten in Symptomatic Nonobstructive Hypertroph…

Jul 8, 2025 · 3 shares · 557 followers View post →
د . احمد سمان
@Ahmed43101178 · X

RT @drbennisahmed: ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:4 Mavacamten in Symptomatic Nonobstructive Hypertroph…

Jul 8, 2025 · 3 shares · 6,403 followers View post →
Ahmed Bennis MD
@drbennisahmed · X

ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:4 Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 symptomatic https://t.co/4RnqNg5GzB

Jul 8, 2025 · 14 likes · 3 shares · 3,249 followers View post →
Center for Genomic Medicine
@UtahCGM · X

New Pub Alert from @UtahCGM! Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM https://t.co/o3jYHgWVaE

Feb 6, 2025 · 297 followers View post →
Tues, September 23 at 8pm ET: Expert Insights on HCM ...
Instagram

Martinez, MD, FACC Director, Hypertrophic Cardiomyopathy and Sports Cardiology Program Atlantic Health System/Morristown Medical Center Med-IQ ...

Sep 18, 2025 View →
For patients with nonobstructive hypertrophic cardiomyopathy (HCM ...
Instagram

El estudio ODYSSEY-HCM examina la efectividad del Mavacamten en pacientes con cardiomiopatía hipertrófica no obstructiva.

Sep 16, 2025 View →
Mavacamten does not improve outcomes in nonobstructive HCM
News

2025;doi:10.1056/NEJMoa2505927. Published by: cardiology today logo. Sources/Disclosures. Source: Desai MY, et al. Hot line 2. Presented at ...

Sep 11, 2025 View →
No improvements with mavacamten in symptomatic nonobstructive ...
News

10.1056/NEJMoa2505927. Keywords. /Health and medicine/Medical specialties/Cardiology. EurekAlert! The Global Source for Science News. AAAS ...

Sep 4, 2025 View →
No improvements found with mavacamten in symptomatic ...
News

DOI: 10.1056/NEJMoa2505927. Journal information: New England Journal of Medicine. Provided by European Society of Cardiology. + Explore further ...

Sep 4, 2025 View →
Hypertrophe Kardiomyopathie: Myosininhibitoren nur bei ...
News

... 10.1056/NEJMoa2504654 und 10.1056/NEJMoa2505927) publiziert. rme. Zum Weiterlesen anmelden. Liebe Leserinnen und Leser,. dieser Beitrag ist nur ...

Sep 3, 2025 View →
Mavacamten No Match for Nonobstructive HCM in Phase III Trial ...
News

... cardiomyopathy" N Engl J Med 2025; DOI: 10.1056/NEJMoa2505927. Comment. Please enable JavaScript to view the comments powered by Disqus.

Aug 30, 2025 View →